Intertek   Report issue

For profit Phase 3
Founded: Mobile AL United States (1996)
Status: No NME R&D (1996)

Organization Overview

First Clinical Trial
2009
NCT00982111
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

INTERTECK | INTERTEK FRANCE

Active Ingredients

Drugs in Phase 3 Trials (4)

cisplatin (platinol) (2 trials)

gemcitabine (gemzar) (1 trial)

necitumumab (portrazza) (2 trials)

pemetrexed (alimta) (1 trial)

Drugs in Other Trials (1)

acetyl tetrapeptide (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 3)

Lung Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 5